Savara Inc. has released a corporate presentation detailing its development of new therapies for rare respiratory diseases. The presentation highlights the company's focus on autoimmune pulmonary alveolar proteinosis (autoimmune PAP), noting the challenges patients face with current treatment options such as whole lung lavage. Savara is advancing MOLBREEVI (molgramostim inhalation solution), which has been conditionally accepted as a trade name by the FDA and EMA, though it is not yet approved for any indication. The company plans to resubmit its Biologics License Application (BLA) for the therapy in December 2025. The executive leadership team and patient experiences are also featured in the presentation. You can access the full presentation through the link below.